Avoiding the use of human chorionic gonadotropin combined with oocyte vitrification and GnRH agonist triggering versus coasting: a new strategy to avoid ovarian hyperstimulation syndrome.
about
Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technologyVitrification versus slow freezing for women undergoing oocyte cryopreservationVitrification versus slow freezing for women undergoing oocyte cryopreservationOocyte, embryo and blastocyst cryopreservation in ART: systematic review and meta-analysis comparing slow-freezing versus vitrification to produce evidence for the development of global guidanceDifferent ART outcomes at increasing peak estradiol levels with long and antagonist protocols: retrospective insights from ten years experience.Ovarian hyperstimulation syndrome after gonadotropin-releasing hormone agonist triggering and "freeze-all": in-depth analysis of genetic predisposition.A combination of hydroxypropyl cellulose and trehalose as supplementation for vitrification of human oocytes: a retrospective cohort study.Ectopic pregnancy risk factors for ART patients undergoing the GnRH antagonist protocol: a retrospective studyGnRH analogues in the prevention of ovarian hyperstimulation syndromeCombination of cabergoline and embryo cryopreservation after GnRH agonist triggering prevents OHSS in patients with extremely high estradiol levels--a retrospective studyCoasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome.The state of "freeze-for-all" in human ARTs.Impact of vitrification on the mitochondrial activity and redox homeostasis of human oocyte.The effect of an immediate frozen embryo transfer following a freeze-all protocol: a retrospective analysis from two centres.The effects of bromocriptine on VEGF, kidney function and ovarian hyperstimulation syndrome in in vitro fertilization patients: a pilot study.
P2860
Q24193015-33F251DC-13DA-4FBA-996B-723E91EC94F6Q24193770-8ECEFB68-C2F6-4574-94B6-6FF6A4DB7C4BQ24201780-1111AD4B-B56D-4D97-BAC5-C2439B26F3A3Q28077375-6F20BB9D-67FB-4304-858B-AB3310E80B1CQ35205814-1620DB85-40C0-44F2-9C29-DB6662B298E1Q35938164-AEBCA140-5817-42EC-8B85-76C66274780BQ36670046-4876E0CD-BB7A-48C3-A5DF-ECC9EE48DFF7Q36720308-08EE7582-9B66-4D09-8724-A7B9D7ED6EB3Q36957480-D928510A-B1F5-486D-B484-6AD683E8D775Q36966423-C5938506-9053-4266-8044-1AF243B6CF86Q38768708-0BD10B61-DEFC-4F99-93AA-58D4B11137FBQ38954609-0D127BB1-3535-4007-8424-F033586B0FADQ39717428-26320881-ACD1-44AF-83DA-C7F342011451Q48542271-F6F39F8F-C6E3-4346-AAF3-64897B0ED638Q55056870-557C05E9-B97C-497C-ACFA-650FCE51AE64
P2860
Avoiding the use of human chorionic gonadotropin combined with oocyte vitrification and GnRH agonist triggering versus coasting: a new strategy to avoid ovarian hyperstimulation syndrome.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Avoiding the use of human chor ...... ian hyperstimulation syndrome.
@en
type
label
Avoiding the use of human chor ...... ian hyperstimulation syndrome.
@en
prefLabel
Avoiding the use of human chor ...... ian hyperstimulation syndrome.
@en
P2093
P1476
Avoiding the use of human chor ...... ian hyperstimulation syndrome.
@en
P2093
Ana Cristina Cobo
Carolina Losada
Juan Antonio Garcia-Velasco
Leyre Herrero
Sandra Pareja
P304
P356
10.1016/J.FERTNSTERT.2010.09.040
P407
P577
2010-11-03T00:00:00Z